Incidence of Guillain-Barré syndrome in an Uruguayan population. A prospective cohort study.
Guillain-Barre syndrome
Uruguay
epidemiology
incidence rate
prospective study
Journal
Journal of the peripheral nervous system : JPNS
ISSN: 1529-8027
Titre abrégé: J Peripher Nerv Syst
Pays: United States
ID NLM: 9704532
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
revised:
08
04
2021
received:
29
12
2020
accepted:
22
04
2021
pubmed:
5
5
2021
medline:
15
2
2022
entrez:
4
5
2021
Statut:
ppublish
Résumé
Guillain-Barre syndrome (GBS) is an acute autoimmune peripheral inflammatory neuropathy and the most frequent cause of non-poliovirus acute flaccid paralysis worldwide. Background annual GBS incidence rates (IRs) in Latin America (LA) varies from 0.40 to 2.12/100000 persons per year. We performed a prospective population-based epidemiological study to determine the incidence and clinical profile of GBS in the most densely populated regions in Uruguay. The incidence of GBS in the population living in Montevideo and Canelones was studied in the period between June 01, 2018 and May 31, 2020. Patients older than 16 years of age diagnosed with GBS were prospectively enrolled. The mean global annual IR in the Uruguayan population was 1.7/100000 persons (95% CI 1.25-2.25). The highest rate was observed in the 65 to 74 age group among men (5.25/100000 per year) and in the 55 to 64 age group among women (2/100.000 per year). The mean age was 53.9 ± 19.5, years, without difference by sex (53.5 women, 54.5 men). The in-hospital mortality rate was 5.8%. A total of 51 patients were diagnosed with GBS: 42 (82%) had typical GBS, 5 (10%) Miller-Fisher syndrome (MFS), 3 (7%) a bilateral facial nerve palsy, 1 patient had a GBS-MFS overlap (2.3%). This is the first population-based GBS incidence study in LA using a prospective design. Our IR can be a useful tool in establishing the background rate to examine future disease trends caused by the introduction of new viruses or vaccines in Uruguay.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
209-215Informations de copyright
© 2021 Peripheral Nerve Society.
Références
Yuki N, Hartung H. Guillain-Barré Syndrome. N Engl J Med. 2012;366:2294-2304.
Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717-727. https://doi.org/10.1016/S0140-6736(16)00339-1.
Sipilä JOT, Soilu-Hänninen M. The incidence and triggers of adult-onset Guillain-Barré syndrome in southwestern Finland 2004-2013. Eur J Neurol. 2015;22(2):292-298. https://doi.org/10.1111/ene.12565.
Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531-1539. https://doi.org/10.1016/S0140-6736(16)00562-6.
Black S, Eskola J, Siegrist C, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet. 2010;374(9707):2115-2122. https://doi.org/10.1016/S0140-6736(09)61877-8.
McGrogan A, Madle GC, Seaman HE, De Vries CS. The epidemiology of Guillain-Barré syndrome worldwide: a systematic literature review. Neuroepidemiology. 2009;32(2):150-163. https://doi.org/10.1159/000184748.
Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123-133. https://doi.org/10.1159/000324710.
Capasso A, Ompad DC, Vieira DL, Wilder-Smith A, Tozan Y. Incidence of Guillain-BarréSyndrome (GBS) in Latin America and the Caribbean before and during the 2015-2016 Zika virus epidemic: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2019;13(8):1-19. https://doi.org/10.1371/journal.pntd.0007622.
Instituto Nacional de Estadistica Uruguay. Censos 2011. http://www.ine.gub.uy.
Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27(1 S):S21-S24. https://doi.org/10.1002/ana.410270707.
Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet. 1978;312(8093):750-753. https://doi.org/10.1016/S0140-6736(78)92644-2.
Ahmad OB, Boschi-pinto C, Lopez AD. Age standardization of rates: a new WHO standard. GPE Discussion Paper Series 2001;(31):1-14. http://www.who.int/healthinfo/paper31.pdf.
Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barré syndrome and fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29(3):599-612. https://doi.org/10.1016/j.vaccine.2010.06.003.
Delannoy A, Rudant J, Chaignot C, Bolgert F, Mikaeloff Y, Weill A. Guillain-Barré syndrome in France: a nationwide epidemiological analysis based on hospital discharge data (2008-2013). J Peripher Nerv Syst. 2017;22(1):51-58. https://doi.org/10.1111/jns.12202.
Benedetti MD, Pugliatti M, Dalessandro R, et al. A multicentric prospective incidence study of Guillain-Barre syndrome in Italy. The ITANG study. Neuroepidemiology. 2015;45(2):90-99. https://doi.org/10.1159/000438752.
Chiò A, Cocito D, Leone M, et al. Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology. 2003;60(7):1146-1150. https://doi.org/10.1212/01.WNL.0000055091.96905.D0.
Benedetti L, Briani C, Beronio A, et al. Increased incidence of axonal Guillain-Barré syndrome in La Spezia area of Italy: a 13-year follow-up study. J Peripher Nerv Syst. 2019;24(1):80-86. https://doi.org/10.1111/jns.12292.
Suryapranata FST, Ang CW, Chong LL, Murk JL, Falconi J, Huits RMHG. Epidemiology of Guillain-Barré syndrome in Aruba. Am J Trop Med Hyg. 2016;94(6):1380-1384. https://doi.org/10.4269/ajtmh.15-0070.
van Koningsveld R, Rico R, Gerstenbluth I, et al. Gastroenteritis-associated Guillain-Barré syndrome on the Caribbean Island Curaçao. Neurology. 2001;56(11):1467-1472. https://doi.org/10.1212/WNL.56.11.1467.
Rivera-Lillo G, Torres-Castro R, Burgos PI, et al. Incidence of Guillain-Barré syndrome in Chile: a population-based study. J Peripher Nerv Syst. 2016;21(4):339-344. https://doi.org/10.1111/jns.12182.
Shui IM, Rett MD, Weintraub E, et al. Guillain-Barré syndrome incidence in a large United States cohort (2000-2009). Neuroepidemiology. 2012;39(2):109-115. https://doi.org/10.1159/000339248.
Huang WC, Lu CL, Chen SCC. A 15-year nationwide epidemiological analysis of Guillain-Barré syndrome in Taiwan. Neuroepidemiology. 2015;44(4):249-254. https://doi.org/10.1159/000430917.
Styczynski AR, Malta JMAS, Krow-Lucal ER, et al. Increased rates of Guillain-Barré syndrome associated with Zika virus outbreak in the Salvador metropolitan area, Brazil. PLoS Negl Trop Dis. 2017;11(8):1-13. https://doi.org/10.1371/journal.pntd.0005869.
Salinas JL, Walteros DM, Styczynski A, et al. Zika virus disease-associated Guillain-Barré syndrome-Barranquilla, Colombia 2015-2016. J Neurol Sci. 2017;381:272-277. https://doi.org/10.1016/j.jns.2017.09.001.
Hense S, Schink T, Kreisel SH, et al. Estimation of background incidence rates of guillain-barré syndrome in Germany-a retrospective cohort study with electronic healthcare data. Neuroepidemiology. 2014;43(3-4):244-252. https://doi.org/10.1159/000369344.
Chen Y, Ma F, Zhang J, Chu X, Xu Y. Population incidence of Guillain-Barré syndrome in parts of China: three large populations in Jiangsu province, 2008-2010. Eur J Neurol. 2014;21(1):124-129. https://doi.org/10.1111/ene.12265.
Peric S, Milosevic V, Berisavac I, et al. Clinical and epidemiological features of Guillain-Barré syndrome in the Western Balkans. J Peripher Nerv Syst. 2014;19(4):317-321. https://doi.org/10.1111/jns.12096.
Cuadrado JI, de Pedro-Cuesta J, Ara JR, et al. Public health surveillance and incidence of adulthood Guillain-Barré syndrome in Spain, 1998-1999: the view from a sentinel network of neurologists. Neurol Sci. 2004;25(2):57-65. https://doi.org/10.1007/s10072-004-0231-6.
Nussinovitch U, Shoenfeld Y. The role of gender and organ specific autoimmunity. Autoimmun Rev. 2012;11(6-7):377-385. https://doi.org/10.1016/j.autrev.2011.11.001.
Giefing-Kröll C, Berger P, Lepperdinger G, Grubeck-Loebenstein B. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell. 2015;14(3):309-321. https://doi.org/10.1111/acel.12326.
Webb AJS, Brain SAE, Wood R, Rinaldi S, Turner MR. Seasonal variation in Guillain-Barré syndrome: a systematic review, meta-analysis and Oxfordshire cohort study. J Neurol Neurosurg Psychiatry. 2015;86(11):1196-1201. https://doi.org/10.1136/jnnp-2014-309056.
Galeotti F, Massari M, D'Alessandro R, et al. Risk of Guillain-Barré syndrome after 2010-2011 influenza vaccination. Eur J Epidemiol. 2013;28(5):433-444. https://doi.org/10.1007/s10654-013-9797-8.
Doets AY, Verboon C, van den Berg B, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018;141(10):2866-2877. https://doi.org/10.1093/brain/awy232.
Al-Hakem H, Sindrup SH, Andersen H, et al. Guillain-Barré syndrome in Denmark: a population-based study on epidemiology, diagnosis and clinical severity. J Neurol. 2019;266(2):440-449. https://doi.org/10.1007/s00415-018-9151-x.
Granieri E, Andreasi NG, De Martin P, et al. Incidence study of Guillain-Barré syndrome in the province of Ferrara, northern Italy, between 2003 and 2017. A 40-year follow-up. Neurol Sci. 2019;40(3):603-609. https://doi.org/10.1007/s10072-018-3688-4.
Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barré syndrome: incidence and mortality rates in US hospitals. Neurology. 2008;70(18):1608-1613. https://doi.org/10.1212/01.wnl.0000310983.38724.d4.
Hafsteinsdóttir B, Ólafsson E, Jakobsson F. Incidence and outcome of Guillain-Barré syndrome in Iceland: a population-based study. Acta Neurol Scand. 2018;138(5):454-458. https://doi.org/10.1111/ane.13000.
Cheng Q, Jiang GX, Fredrikson S, Link H. DP-CJ. Incidence of Guillain-Barré syndrome in Sweden 1996. Eur J Neurol. 2000;7(1):130-139.
Sipilä JOT, Soilu-Hänninen M, Ruuskanen JO, Rautava P, Kytö V. Epidemiology of Guillain-Barré syndrome in Finland 2004-2014. J Peripher Nerv Syst. 2017;22(4):440-445. https://doi.org/10.1111/jns.12239.